Moritz M. Reichert

Advanced Clinical Research Fellow at Oxford University Hospitals

[Blood Cancer UK @bloodcancer_uk]

Blood Cancer Awareness Month starts today ❤️

Blood cancer changes everything. Whether you’re living with it, have been through it, supporting someone you love, or remembering someone you’ve lost - this month is for you.

Share this to help us raise awareness.

[Moritz M. Reichert @MoritzMReichert]

@ARampotas @giulianopy88 @ScienceTM Truly great work Alex, so glad to see it published!

[Alex Rampotas @ARampotas]

1/ 🧵 So delighted to share our new paper, out today in Science Translational Medicine @ScienceTM. We built a CAR-T cell therapy that selectively depletes the disease-driving mutant calreticulin (mutCALR) cells in myelofibrosis — while sparing healthy blood stem cells👇

https://t.co/zfwYYSqT9h

[Alex Rampotas @ARampotas]

Excited to share our new paper in @BrJHaem , led with @DrLornan on behalf of the UK Blood Cancer Research Network MPN Clinical Study Group 🧵
Real-world treatment patterns & outcomes in accelerated and blast-phase MPNs — the largest UK cohort to date.
👇 https://t.co/ixUnooQuJW

[richard white @whitefishlab]

My department at Oxford is recruiting junior faculty to the Ludwig Institute for Cancer Research. A collaborative and stimulating department, with great access to the breadth of the Oxford environment. The positions come with core funding and cutting edge technologies. If interested, apply here: https://t.co/R5Lah3bZB3

[Moritz M. Reichert @MoritzMReichert]

New work in HemaSphere on mutant celreticulin in Essential Thrombocythaemia📄

The biology is remarkable: a cancer-driving oncogene that displays its own product on the cell surface as a neoantigen. A built-in target 🎯

Open access: https://t.co/0M41iqGYEp
#MPN #CALR #EHA #Hem

[Moritz M. Reichert @MoritzMReichert]

@ARampotas 😂

[Moritz M. Reichert @MoritzMReichert]

@tobi I’m pretty confident this is not L3-L5. Although it looks nice, I’m not convinced yet by one-shot medical capabilities

[Alex Rampotas @ARampotas]

The field of MF is changing rapidly and the decision on the timing of allo-HCT will become even harder. Here we show where we are are now by surveying 19 transplant centres. Many thanks to @DrLornan @JAspaCilleruelo and the @TheEBMT CMWP for the coordination of the study #MPNsm

[Graham Collins @graham74GC]

Looking for a job which trains you in early phase clinical trials in lymphoid malignancies?

Look no further!

The Oxford early phase clinical trials unit is advertising for a fellow. See link and if you're thinking of applying do get in touch.

https://t.co/gsHgXr9P74

[Moritz M. Reichert @MoritzMReichert]

Does the news reflect what we die from? Brilliant overview from Our World In Data. Cancer still #2 despite incredible progress! https://t.co/MG7EPZFjVe

[richard white @whitefishlab]

I am (no joke) interested in trying this in my lab at @UniofOxford . It seems very likely we could use an agentic-enabled robot to do DNA/RNA preps, qPCR etc. @GoogleAI - any interest in a pilot?

[Albert Suheil Atallah-Yunes @AlbertYunes]

Excited to share our multi-institutional study on ALK+ Large B-cell lymphoma in @AjHematology :
Outcomes remain poor with intensified chemo and consolidative ASCT. Select durable remissions occurred with biologically targeted therapies & allo-SCT
https://t.co/3LgZWUjDIx

[Moritz M. Reichert @MoritzMReichert]

Incredibly important work and a brilliant use of a huge dataset

[Iain S. Forrest, MD-PhD @IainSForrest]

Most genetic reports label variants as ✅ “pathogenic” or ❌ “benign.”
But what patients really want to know is: what are my chances of getting the disease?
🚨 In our new Science study, we used AI + 1.3M patient records to better answer that…

[European Hematology Association @EHA_Hematology]

Are you looking to enhance your clinical hematology research skills? Due to popular demand, we've extended the application deadline for our 2026 Clinical Research Training in Hematology (#CRTH) program until the 16th of September at 15:00 (CEST).

Successful applicants will benefit from:
📌 Learn how to design and execute a clinical trial
📌 Develop a strategy for effective collaboration with various stakeholders
📌 Recognize the ethical and regulatory framework relevant to clinical research
📌 Examine the fundamentals of competitive grant and abstract writing and manuscript preparation and presentation
📌 Understand and apply the basic principles of meta-analyses, and learn how to use statistics effectively

All costs associated with participating in CRTH are covered by EHA.

Apply now: https://t.co/db9wtwlAhW

[David Steensma, MD @DavidSteensma]

What a cool story by @beth_psaila and colleagues in @ScienMagazine

Platelets can shuttle around DNA 🧬 that they pick up - a little like USB drives carrying information from place to place, but sometimes it’s malware ☠️

https://t.co/OcD977Alk3

[Eric Topol @EricTopol]

Platelets sequester and harbor cell-free tumor DNA, which could enhance our ability to make early, microscopic diagnosis of cancer
@ScienceMagazine
https://t.co/Z6W7Wxz1Bo
https://t.co/QkjiIgUydB

[European Hematology Association @EHA_Hematology]

There is less than a month to submit your application and join our 2026 research trainings cohort! Whether you're a #computationalbiologist (CBTH) or a #clinicalresearcher (CRTH), you'll gain access to an unparalleled, in-person #mentoring and #coaching experience.

How will I benefit from joining? 
📈 Accelerate your career in hematology research by hearing from top-tier experts who share scientific expertise and career lessons.
🧠 Gain knowledge on how to be a principal investigator.
🗺️ Develop your skills during two in-person workshops and a session at the EHA Annual Congress.
👨‍⚕️ Widen your network of potential collaborators, including new peers and potential mentors.

Applications for CBTH & CRTH close at 15:00 (CEST) on September 2, 2025. 
Apply as a computational biologist for CBTH: https://t.co/SWxInbWYda
Apply as a clinical researcher for CRTH: https://t.co/iHvqvMYu7D

[Gaby Hobbs @GabyHobbs]

👉⭐️Truly thrilled to see this in press- Rux-before, during, after-HCT for MF = very low GVHD and excellent PFS/OS. Thank you to all the sites, PIs, Incyte for supporting this and most of all our patients! JCO OA 😀https://t.co/4PmiFvLVmM
#MPNSM #MGH

[Moritz M. Reichert @MoritzMReichert]

Are we already experiencing peak AI for LLMs? OpenAI has brought back GPT-4o, a mere day after GPT-5 was released (https://t.co/kjLzgwiZ5p). Will we see future developments in small increments only, like the smartphone world? #AI #llm